How to use virological tools for optimal management of chronic hepatitis C
- 21 January 2009
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 29 (s1) , 9-14
Abstract
Chronic hepatitis C is a global health problem that may cause cirrhosis and progression to hepatocellular carcinoma. Currently available antiviral treatments are moderately effective. Several virological assays are available to help diagnose and manage patients infected with the hepatitis C virus (HCV). These include the anti‐HCV antibody assays, measurement of HCV RNA viral load and HCV genotyping. HCV RNA can be assayed by two types of molecular biology‐based techniques: target amplification as in polymerase chain reaction methods and signal amplification such as the branched DNA assay. Monitoring of viral kinetics during the early phases of antiviral treatment is crucial in making treatment decisions such as early stopping rules and also in optimizing the length of treatment. The HCV genotype can be determined by several methods. Whatever the method, pretreatment determination allows treatment length and ribavirin dose to be optimized and also offers prognostic information on treatment outcomes as certain genotypes respond more favourably to treatment. Thus, virological assays are indispensable in the diagnosis and management of individuals infected with the HCV.Keywords
This publication has 25 references indexed in Scilit:
- Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis CLiver International, 2008
- Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0Journal of Clinical Microbiology, 2008
- Anti-HCV IgG avidity index in acute hepatitis CJournal of Clinical Virology, 2007
- Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV AssayJournal of Clinical Microbiology, 2007
- Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of TreatmentGastroenterology, 2006
- 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’Journal of Hepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2006
- Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titresJournal of Hepatology, 2005
- A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 2005
- Immunoglobulin M reactivity towards the inununologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infectionJournal of Medical Virology, 1993